Can Semaglutide Slow Aging? Old Mice Lived 12% Longer
Semaglutide, the active ingredient in Ozempic and Wegovy, appeared to slow several features of aging—in mice. A new study raises an intriguing question about these medicines, but its longevity findings are animal evidence.
The study, published in Nature on September 2, 2026, examined treatment started late in life. The results are worth a closer look, with a clear distinction between what was measured in mice and what remains unknown in people.
Here is what the researchers found—and how to read the findings without turning them into a promise about human aging.
What the study found
The researchers started treatment in 20-month-old female C57BL/6 mice—an age when these animals were already well into later life. This was a late-life intervention, rather than treatment begun in young animals.
The mice received daily semaglutide injections or a control injection. Treatment continued for life in the survival study; separate groups were used to assess function and biological changes.
1. Median lifespan increased. It rose from 742 to 834 days—92 days, or about 12% longer. These figures describe total lifespan, not the time remaining after treatment began. They cannot be converted into extra years of human life.
2. Several measures of function improved. Compared with controls, treated mice performed better on tests of:
- movement and exploration in unfamiliar environments;
- spatial memory (the Barnes maze);
- coordination (rotarod), muscle function and treadmill endurance;
- blood-sugar regulation (glucose tolerance).
3. Weight loss was predominantly fat loss. Food intake fell by about 24%, and the proportion of lean mass increased. A higher lean-mass percentage should not be read as proof that absolute muscle mass increased or that muscle loss cannot occur.
4. Some benefits went beyond calorie restriction alone. The researchers also compared semaglutide with a matched 24% reduction in calorie intake. This helped examine whether eating less could explain the functional findings.
Both interventions benefited several measures. Semaglutide showed more favorable changes in exploratory behavior, spatial memory and glucose control. This does not establish that it outperforms calorie restriction for every outcome, or that it extends lifespan more than calorie restriction.
5. Several molecular hallmarks shifted in a favorable direction. These included chronic inflammation, cellular senescence, mitochondrial dysfunction and genomic instability. Such measurements help researchers investigate aging biology; they do not establish an equivalent effect in humans.
Now the part the headlines skip
The study offers evidence about aging in this mouse model. It does not tell us whether semaglutide will extend your life. Several limits matter when interpreting it.
Mice are not small people. A controlled animal experiment cannot capture the genetic diversity, environments, illnesses and treatment histories of older adults. Translation to humans requires direct clinical evidence.
The model was limited. These findings come from female mice of one strain under a particular treatment regimen. They do not establish the same effects in males, other strains or people. Independent replication would strengthen confidence in how broadly the results apply.
The dosing cannot be carried over directly. This experiment used daily injections in mice. It does not establish a human anti-aging dose or schedule, and it provides no basis for adjusting a prescribed regimen.
Muscle and bone still matter clinically. In older adults, preserving muscle and bone during substantial weight loss remains an important clinical concern. The mouse body-composition findings do not settle that question in people, and this study does not demonstrate that GLP-1 treatment causes fractures.
“Lived longer” and “aged slower” are different questions. A survival result alone cannot identify why animals lived longer. Functional and molecular measurements add context, but they do not completely explain the mechanisms behind the lifespan difference.
The human longevity question remains open. This animal study was not a trial of aging in healthy older adults. Benefits established for a particular medical condition should not be treated as proof of a general anti-aging effect.
Here is where I'd land as a clinician reading this paper.
Do not start semaglutide for longevity on the basis of this study. It establishes neither a human longevity benefit nor a treatment regimen for that purpose. Decisions about medication should rest on your own clinical needs and a discussion with your clinician.
If you already take one of these medicines for a medical condition, this mouse study is not a reason to change your treatment. Discuss nutrition, physical function and weight-loss goals with your treating clinician, especially if you are an older adult.
What makes this research encouraging is its late-life starting point. The animals were already old when treatment began. That makes the study a useful reason to investigate late-life interventions further, while keeping expectations grounded in the model actually tested.
So: watch this space, but watch it for the right signal. The next question is whether well-designed human studies show benefits that matter to older adults, such as preserved mobility, cognition and independence. For now, keeping the authors’ interpretation within the boundaries of this study, the honest answer to “does semaglutide slow aging?” is "it does in old female mice, and that is a real finding, and it is not yet a fact about you."
This post is a plain-language summary of published research and is not medical advice. Do not start, stop or change any medication based on it — talk to your own clinician.
Source
Feng, Y., Barthez, M., Wang, Y. et al. Late-life semaglutide treatment slows ageing and extends lifespan in female mice. Nature (2026). doi.org/10.1038/s41586-026-10940-7
Additional reporting: National Institutes of Health news release
Comments
Post a Comment